Browse Drug Recalls
989 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 989 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 989 FDA drug recalls in TN.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Apr 2, 2019 | Serum Tears 50% Ophthalmic Drops, 1 mL Dropper, Anderson Compounding Pharmacy... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Prostaglandin Tri-Mix 20:25:1 Injection, 2 mL Vial, Anderson Compounding Phar... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Prostaglandin Tri-Mix 20:30:1, 10 mL Vial, Anderson Compounding Pharmacy 310 ... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Prostaglandin Quad with Atropine 10:30:1:0.15, 2 mL Vial, Anderson Compoundin... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Sermorelin 0.3 mg/0.5 mL, 10 mL Vial, Anderson Compounding Pharmacy 310 Bluff... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Heparin 20,000 U/Lidocaine 2% 10 mL/Sodium Bicarbonate 8.4% 10 mL/Sterile Wat... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Heparin 10 mL/ Marcain 0.25% 20 mL/Sodium Bicarbonate 8.4%-40 mL/ Normal Sali... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | DMSO 50% 60 mL/Heparin 1 mL/ Sodium Bicarbonate 60 mL/ Solu-Cortef 100 mg, 41... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Vitamin D3 200,000 IU/mL Injection, 2 mL Vial, Anderson Compounding Pharmacy ... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Heparin 10 mL/Marcaine 0.25% 20 mL/Sodium Bicarbonate 40 mL/Normal Saline 5 m... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | HCG 23 Day, 2876 Units/4.6 mL Vial, Anderson Compounding Pharmacy 310 Bluff C... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Heparin 10 mL/Marcain 0.25% 20 mL/Sodium Bicarbonate 8.4%-40 mL/per 70 mL, An... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | Heparin 2 mL/Lidocaine 2%-10 mL/Sodium Bicarbonate 8.4%-5mL/ Sterile Water 10... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Apr 2, 2019 | HCG 4,100 Units/vial Injection, Anderson Compounding Pharmacy 310 Bluff City ... | Lack of sterility assurance. | Class II | Anderson Compounding Pharmacy, Inc. DBA Anderso... |
| Mar 5, 2019 | Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg 50 Tabl... | CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified | Class II | AVKARE Inc. |
| Mar 5, 2019 | Losartan Potassium Tablets USP 50 mg 50 Tablets (5x10) Unit Dose boxes, Rx On... | CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified | Class II | AVKARE Inc. |
| Mar 5, 2019 | Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 50 Tab... | CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified | Class II | AVKARE Inc. |
| Mar 1, 2019 | Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 4... | Failed Dissolution Specifications | Class III | AVKARE Inc. |
| Feb 20, 2019 | Topical Solution USP Hydrogen Peroxide First Aid Antiseptic Oral Debriding Ag... | Cross Contamination: Presence of IPA in finished product. | Class II | Vi-Jon, Inc. |
| Jan 16, 2019 | Docusate Sodium, 100mg softgels, packaged in 10 x 10 unit dose blister cards,... | Labeling: Label mix-up: Secondary carton may be labeled as Gabapentin 300mg instead of Docusate S... | Class II | Rx Pak Division of McKesson Corporation |
| Dec 17, 2018 | Progesterone 100 mg SR capsules, 30-180 capsules per prescription, Rx only, ... | Lack of Processing Controls. | Class II | Duren Health Mart Pharmacy |
| Dec 17, 2018 | Promethazine Gel 50 mg/mL, 1cc to 10cc per prescription, Rx only, Duren's He... | Lack of Processing Controls. | Class II | Duren Health Mart Pharmacy |
| Dec 17, 2018 | Omeprazole 4 mg/mL Suspension, 150cc to 300 cc per prescription, Rx only, Du... | Lack of Processing Controls. | Class II | Duren Health Mart Pharmacy |
| Dec 17, 2018 | Testosterone 0.1% cream, 30 grams, Rx only, Duren's Health Mart Pharmacy 215 ... | Lack of Processing Controls. | Class II | Duren Health Mart Pharmacy |
| Dec 17, 2018 | Progesterone 10% cream, 12gm to 30gm per prescription, Rx only, Duren's Healt... | Lack of Processing Controls. | Class II | Duren Health Mart Pharmacy |
| Dec 17, 2018 | Domperidone 10 mg capsules, 100-count per prescription, Rx only, Duren's Hea... | Lack of Processing Controls. | Class II | Duren Health Mart Pharmacy |
| Nov 20, 2018 | Germ Bloc Health Hand Sanitizer Foam (benzalkonium chloride 0.13%) 7.5fl.oz./... | Microbial Contamination of Non-Sterile Product: Presence of Pseudomonas aeruginosa in product | Class II | AVKARE Inc. |
| Aug 14, 2018 | Megestrol Acetate Oral Suspension, USP 400 mg/mL, 10 mL (10 mL UD cups in box... | Supterpotent Drug | Class II | Mckesson Corporation |
| Aug 14, 2018 | Valsartan Tablets, USP 80 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-78... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | AVKARE Inc. |
| Aug 14, 2018 | Valsartan Tablets, USP 320 mg Rx Only 30 Tablets (6x5) Unit Dose NDC 50268-78... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | AVKARE Inc. |
| Aug 14, 2018 | Valsartan Tablets, USP 160 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-7... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | AVKARE Inc. |
| Aug 14, 2018 | Valsartan Tablets, USP 40 mg Rx Only NDC 50268-783-15 50 Tablets (5x10) Unit ... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | AVKARE Inc. |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 320 mg/25 mg tablets 90-count bottle... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 80 mg/12.5 mg tablets, 90-count bott... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets, 90-count bot... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 160 mg/25 mg tablets, 90-count bottl... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Jul 18, 2018 | AvKARE Valsartan and Hydrochlorothiazide 320 mg/12.5 mg tablets, 90-count bot... | CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. | Class II | Avkare Incorporated |
| Mar 30, 2018 | Amantadine HCl Capsules, USP, 100 mg, 50 Capsules (5x10) Unite Dose, Rx Only,... | Failed Dissolution Specifications | Class II | AVKARE Inc. |
| Jan 12, 2018 | HCG 5,000 IU/mL + Methylcobalamin 500 mcg/mL Injection 5 mL, Multi-Dose Vial,... | Non-Sterility | Class I | The Compounding Pharmacy of America |
| Jan 3, 2018 | Lovastatin Tablets USP, 40 mg, 50 Tablets (5x10) Unit Dose carton, Rx only, M... | Failed Dissolution Specifications: Low out of specification results for dissolution during annual... | Class II | AVKARE Inc. |
| Oct 13, 2017 | Hydromorphone HCl 0.5 mg per mL in 0.9% Sodium Chloride Injection 1 mL, packa... | Superpotent drug: out of specification result for potency | Class II | PharMEDium Services, LLC. |
| Oct 6, 2017 | Duloxetine Delayed-release Capsules USP, 20 mg, 50 Capsules (5 x 10) Unit Dos... | Failed Impurities/Degradation Specifications: slightly elevated levels of phthalic acid. | Class II | AVKARE Inc. |
| Sep 13, 2017 | Magnesium Citrate Oral Solution Lemon Flavor, 1.745g per fl oz, packaged in ... | Failed Impurities/Degradation Specifications. | Class III | Vi-Jon, Inc. |
| Sep 13, 2017 | Equate Beauty Clarifying Face Daily Moisturizer 4 fl. oz. (118 mL) Distribute... | Failed Stability Specifications | Class III | Vi-Jon, Inc. |
| Sep 13, 2017 | Magnesium Citrate Oral Solution Cherry Flavor, 1.745 g per fl oz, packaged in... | Failed Impurities/Degradation Specifications. | Class III | Vi-Jon, Inc. |
| Jul 19, 2017 | Voriconazole Tablets, 200 mg, 20-count cartons (4 x 5) Unit Dose, Rx only, Ma... | Failed impurities/degradation specifications: Out of specification for a related compound C. | Class III | AVKARE Inc. |
| Jul 17, 2017 | Magnesium Citrate Oral Solution, packaged in a 10 fl. oz. (296 mL) glass bott... | Microbial contamination of non-sterile products: product was found to contain mold, identified as... | Class II | Vi-Jon, Inc. |
| Jun 12, 2017 | Magnesium Citrate Saline Laxative Cherry Flavored, packaged in a) 10 fl. oz. ... | Presence of foreign substance: glass particle | Class II | Vi-Jon, Inc. |
| Feb 15, 2017 | Famciclovir tablets, 500 mg, packaged in 30-count unit dose cartons, Rx only,... | Failed impurities/ degradation specifications: Product was above specification for unknown impuri... | Class II | AVKARE Inc. |
| Dec 12, 2016 | VirtPrex Prenatal/Postnatal Tablets, Prescription Supplement Containing Folic... | cGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert. | Class III | VIRTUS PHARMACEUTICALS OPCO II L |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.